Famotidine is used as the active pharmaceutical ingredient in both oral and injectable famotidine medications. This drug is an H2 histamine receptor antagonist, primarily employed to reduce gastric acid secretion. Famotidine is mainly prescribed for the treatment of gastric and duodenal ulcers, gastroesophageal reflux disease (GERD), acid-related indigestion, and for the prevention of gastrointestinal bleeding in hospitalized patients.
Famotidine works by inhibiting H2 receptors on the parietal cells of the stomach, thereby decreasing gastric acid secretion. Compared to previous generations of H2 antagonists, famotidine offers higher efficacy and fewer side effects. It can be administered orally or via injection and is generally well tolerated by patients.
Pantoprazole is used as the active pharmaceutical ingredient in both oral and injectable formulations of pantoprazole. As a member of the proton pump inhibitor (PPI) class, this medication is primarily prescribed for the treatment of gastroesophageal reflux disease (GERD), gastric and duodenal ulcers, Zollinger-Ellison syndrome, and other conditions associated with excessive gastric acid secretion.
Pantoprazole works by irreversibly inhibiting the proton pump (H+/K+ ATPase) in the gastric parietal cells, resulting in a significant reduction in gastric acid secretion. This action helps alleviate symptoms of heartburn, promotes the healing of gastrointestinal ulcers, and prevents their recurrence.
Lansoprazole, marketed under the brand name Prevacid, is a leading drug in the proton pump inhibitor (PPI) class, playing a crucial role in reducing gastric acid secretion. Approved by the U.S. Food and Drug Administration (FDA) since 1995, lansoprazole is widely prescribed around the world for the management of acid-related gastrointestinal diseases.
The primary indications for lansoprazole include the treatment of gastric and duodenal ulcers, GERD, Zollinger-Ellison syndrome, and the prevention of NSAID-induced gastric ulcers. Additionally, lansoprazole is used in combination with antibiotics for the eradication of Helicobacter pylori infections. Lansoprazole acts by irreversibly inhibiting the H+/K+ ATPase enzyme, commonly known as the proton pump, located in the parietal cells of the stomach lining.